| Recruitment status | Terminated |
| Unique ID issued by UMIN | UMIN000033554 |
| Receipt No. | R000038262 |
| Scientific Title | The study for predictive markers of vessel invasion of gastric cancer |
| Date of disclosure of the study information | 2018/08/01 |
| Last modified on | 2022/02/04 (Ver. 5) |
| Basic information | ||
| Public title | The study for predictive markers of vessel invasion of gastric cancer | |
| Acronym | The study for predictive markers of vessel invasion of gastric cancer | |
| Scientific Title | The study for predictive markers of vessel invasion of gastric cancer | |
| Scientific Title:Acronym | The study for predictive markers of vessel invasion of gastric cancer | |
| Region |
|
|
| Condition | ||
| Condition | Gastric cancer | |
| Classification by specialty |
|
|
| Classification by malignancy | Malignancy | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To analyze whether the results of immunohistochemical staining of biopsy specimens correlate to the degree of vessel invasion of resection specimens |
| Basic objectives2 | Others |
| Basic objectives -Others | To analyze whether the results of immunohistochemical staining of biopsy specimens correlate to the degree of vessel invasion of resection specimens, and to investigate the predictive markers of vessel invasion of gastric cancer |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | Others |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | Discrimination ability of vessel invasion by immunohistochemical staining of beta-catenin, E-cadherin, sox10 and EGFR
1. The relevance between the membrane positive rate of beta-catenin and the degree of vessel invasion 2. The relevance between the membrane positive rate of E-cadherin and the degree of vessel invasion 3. The relevance between the positive rate of sox10 and the degree of vessel invasion 4. The relevance between the positive rate of EGFR and the degree of vessel invasion |
| Key secondary outcomes | 1. The concordance rate of histology of biopsy specimen and resection specimen
2. The concordance rate of immunohistochemistry of biopsy specimen and resection specimen 3. The relevance between vessel invasion and histology 4. The relevance between vessel invasion and infiltration type 5. The relevance between vessel invasion and progression free survival 6. The relevance between vessel invasion and overall survival 7. The relevance between the result of immunohistochemical staining of each molecule and histology 8. The relevance between the result of immunohistochemical staining of each molecule and infiltration type 9. The relevance between the result of immunohistochemical staining of each molecule and progression free survival 10. The relevance between the result of immunohistochemical staining of each molecule and overall survival |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1. Patients who are 20 years of age or older at the time of obtaining informed consent
2. Patients who are diagnosed as gastric cancer by biopsy 3. Patients who are resected stomach as treatment for gastric cancer 4. Patients who are informed and have provided written informed consent to participate in the study prior to study initiation |
|||
| Key exclusion criteria | 1. Patients by whom principal investigator has determined to be inappropriate as a subject | |||
| Target sample size | 153 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Hokkaido University Hospital | ||||||
| Division name | Department of Gastroenterology and Hepatology | ||||||
| Zip code | 0608648 | ||||||
| Address | North 14, West 5, Kita-ku, Sapporo-shi, Hokkaido, Japan | ||||||
| TEL | +81-11-716-1161 | ||||||
| onosho@med.hokudai.ac.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Hokkaido University Hospital | ||||||
| Division name | Division of Endoscopy | ||||||
| Zip code | 0608648 | ||||||
| Address | North 14, West 5, Kita-ku, Sapporo-shi, Hokkaido, Japan | ||||||
| TEL | +81-11-716-1161 | ||||||
| Homepage URL | |||||||
| marin.0719@med.hokudai.ac.jp | |||||||
| Sponsor | |
| Institute | Hokkaido University Hospital |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Hokkaido University Hospital |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Clinical Research Audit Committee, Hokkaido University Hospital |
| Address | North 14, West 5, Kita-ku, Sapporo-shi, Hokkaido, Japan |
| Tel | +81-11-706-7636 |
| crjimu@huhp.hokudai.ac.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | 128 |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Terminated | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | 1. The relevance between the membrane positive rate of beta-catenin and the degree of vessel invasion
2. The relevance between the membrane positive rate of E-cadherin and the degree of vessel invasion 3. The relevance between the positive rate of sox10 and the degree of vessel invasion 4. The relevance between the positive rate of EGFR and the degree of vessel invasion |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000038262 |